Transplants Made to Order

FEATURE Transplants Made to Order © THOMAS RÖPKE/CORBIS Tissue engineering tackles its most formidable challenge - mimicking nature. By GORDANA VUNJAK-NOVAKOVIC The possibility that we might engineer replacements for worn out tissues - from the simple slips of cartilage that cushion joints to fully differentiated, functional grafts in a ready-to-use format - is increasingly plausible. The need is obvious. With advances in medi

Written byGordana Vunjak-Novakovic
| 12 min read

Register for free to listen to this article
Listen with Speechify
0:00
12:00
Share

Tissue engineering tackles its most formidable challenge - mimicking nature.
By GORDANA VUNJAK-NOVAKOVIC

The possibility that we might engineer replacements for worn out tissues - from the simple slips of cartilage that cushion joints to fully differentiated, functional grafts in a ready-to-use format - is increasingly plausible. The need is obvious. With advances in medicine, we are outliving the functional life of our organs. Roughly one in five people reaching the age of 65 will benefit from some kind of tissue replacement or transplant in their lifetime,1 but due to poor availability, many will not. While visions of a healthy, shrink-wrapped heart ready to drop in the

chest cavity of a needy patient are pure fantasy for now, tissue engineering is remarkably close to producing biological grafts that can reestablish normal tissue structure and function across different size scales, on a long term, and with the ability to remodel in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies